A5044885002- Skin and Cellular Biology Research
- Silk-based biomaterials and applications
- Transgenic Plants and Applications
- Viral Infectious Diseases and Gene Expression in Insects
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- Immune cells in cancer
- Dermatological and Skeletal Disorders
- Pluripotent Stem Cells Research
- Cellular Mechanics and Interactions
- Animal Genetics and Reproduction
- Cancer Immunotherapy and Biomarkers
- Dermatology and Skin Diseases
- Cutaneous lymphoproliferative disorders research
- Eosinophilic Disorders and Syndromes
- Endometriosis Research and Treatment
- Reproductive System and Pregnancy
- Tissue Engineering and Regenerative Medicine
- Stress Responses and Cortisol
- Skin Protection and Aging
- Reproductive Physiology in Livestock
- Melanoma and MAPK Pathways
- Cell Adhesion Molecules Research
- Oral Health Pathology and Treatment
- Biosimilars and Bioanalytical Methods
Columbia University
2017-2024
Columbia University Irving Medical Center
2019
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited skin disorder caused by mutations in the COL7A1 gene encoding type VII collagen (C7). The spectrum of severity depends on mutation gene. C7 major constituent anchoring fibrils (AFs) at basement membrane zone (BMZ). Patients with RDEB lack functional and have severely impaired dermal-epidermal stability, resulting extensive blistering open wounds that greatly affect patient's quality life. There are currently no therapies...
Abstract We present Dystrophic Epidermolysis Bullosa Cell Therapy (DEBCT), a scalable platform producing autologous organotypic iPS cell-derived induced skin composite (iSC) grafts for definitive treatment. Clinical-grade manufacturing integrates CRISPR-mediated genetic correction with reprogramming into one step, accelerating derivation of COL7A1 -edited cells from patients. Differentiation epidermal, dermal and melanocyte progenitors is followed by CD49f-enrichment, minimizing maturation...
Summary Background Gene editing in induced pluripotent stem (iPS) cells has been hailed to enable new cell therapies for various monogenetic diseases including dystrophic epidermolysis bullosa (DEB). However, manufacturing, efficacy and safety roadblocks have limited the development of genetically corrected, autologous iPS cell-based therapies. Methods We developed Dystrophic Epidermolysis Bullosa Cell Therapy (DEBCT), a generation GMP-compatible (cGMP), reproducible, scalable platform...
Abstract Atopic dermatitis (AD), driven by interleukins (IL‐4/IL‐13), is a chronic inflammatory skin disease characterized intensive pruritus. However, it unclear how immune signaling and sensory response pathways cross talk with each other. We differentiated itch neuron‐like cells (ISNLCs) from iPSC lines. These ISNLCs displayed neural markers action potentials responded specifically to itch‐specific stimuli. expressed receptors specific for IL‐4/IL‐13 were activated directly the two...
Summary Immunotherapy is a treatment for many types of cancer, primarily due to deep and durable clinical responses mediated by immune checkpoint blockade (ICB) 1, 2 . Prostate cancer notable exception in that it generally unresponsive ICB. The standard advanced prostate androgen-deprivation therapy (ADT), form castration (CTX). ADT initially effective, but over time patients eventually develop castration-resistant (CRPC). Here, we focused on defining tumor-cell intrinsic factors contribute...